STOCK TITAN

Recursion announces first patient dosed in Phase 2 clinical study of REC-3964, a potential first-in-class, oral, non-antibiotic small molecule for recurrent Clostridioides difficile infection

Rhea-AI Impact
(Moderate)
Rhea-AI Sentiment
(Neutral)

Recursion (NASDAQ: RXRX) has dosed the first patient in its Phase 2 clinical trial of REC-3964, an oral, non-antibiotic small molecule designed for recurrent Clostridioides difficile (C. diff) infection. The novel treatment selectively inhibits the glucosyltransferase activity of toxin B produced by C. diff, aiming to prevent recurrence while sparing the gut microbiome. C. diff infections cause significant morbidity and mortality, with up to 175,000 recurrent cases annually in the U.S. and high recurrence rates post-antibiotic treatment. Preclinical studies showed REC-3964's superiority over bezlotoxumab, and Phase 1 trials demonstrated its safety and tolerability. The Phase 2 ALDER trial will enroll around 80 participants across the U.S. and Europe to assess safety, tolerability, pharmacokinetics, and efficacy.

Recursion (NASDAQ: RXRX) ha trattato il primo paziente nel suo studio clinico di fase 2 per il REC-3964, una molecola piccola orale, non antibiotica, progettata per l'infezione ricorrente da Clostridioides difficile (C. diff). Il nuovo trattamento inibisce selettivamente l'attività della glucosiltransferasi della tossina B prodotta da C. diff, mirando a prevenire la ricorrenza pur preservando il microbioma intestinale. Le infezioni da C. diff causano una significativa morbilità e mortalità, con fino a 175.000 casi ricorrenti ogni anno negli Stati Uniti e alte percentuali di ricorrenza dopo il trattamento antibiotico. Studi preclinici hanno dimostrato la superiorità di REC-3964 rispetto al bezlotoxumab, e gli studi di fase 1 hanno dimostrato la sua sicurezza e tollerabilità. Lo studio di fase 2 ALDER arruolerà circa 80 partecipanti negli Stati Uniti e in Europa per valutare sicurezza, tollerabilità, farmacocinetica ed efficacia.

Recursion (NASDAQ: RXRX) ha administrado el primer paciente en su ensayo clínico de fase 2 de REC-3964, una molécula pequeña oral, no antibiótica, diseñada para la infección recurrente por Clostridioides difficile (C. diff). El nuevo tratamiento inhibe selectivamente la actividad de la glucosiltransferasa de la toxin B producida por C. diff, con el objetivo de prevenir la recurrencia mientras preserva el microbioma intestinal. Las infecciones por C. diff causan una morbilidad y mortalidad significativas, con hasta 175,000 casos recurrentes anualmente en EE. UU. y altas tasas de recurrencia tras el tratamiento antibiótico. Los estudios preclínicos mostraron la superioridad de REC-3964 sobre el bezlotoxumab, y los ensayos de fase 1 demostraron su seguridad y tolerabilidad. El ensayo de fase 2 ALDER inscribirá alrededor de 80 participantes en EE. UU. y Europa para evaluar la seguridad, la tolerabilidad, la farmacocinética y la eficacia.

Recursion (NASDAQ: RXRX)는 재발성 Clostridioides difficile (C. diff) 감염을 위해 설계된 경구용 비항생제 소분자 REC-3964의 2상 임상 시험에서 첫 환자를 등록했습니다. 이 새로운 치료법은 C. diff가 생성한 독소 B의 글루코실트랜스퍼레이스 활성을 선택적으로 억제하여 재발을 예방하고 장내 미생물군을 보호하는 것을 목표로 합니다. C. diff 감염은 상당한 이환율과 사망률을 초래하며, 미국에서 매년 175,000건의 재발성 사례가 발생하고 항생제 치료 후 높은 재발률을 보입니다. 사전임상 연구에서는 REC-3964가 베졸록수맙보다 우수함을 보여주었고, 1상 시험에서는 안전성과 내약성이 입증되었습니다. 2상 ALDER 시험에서는 안전성, 내약성, 약동학 및 효능을 평가하기 위해 미국과 유럽에서 약 80명의 참가자가 등록될 예정입니다.

Recursion (NASDAQ: RXRX) a traité le premier patient dans son essai clinique de phase 2 pour le REC-3964, une petite molécule orale, non antibiotique, conçue pour les infections récurrentes à Clostridioides difficile (C. diff). Ce nouveau traitement inhibe sélectivement l'activité de la glucosyltransférase de la toxine B produite par C. diff, visant à prévenir la récidive tout en préservant le microbiome intestinal. Les infections à C. diff causent une morbidité et une mortalité significatives, avec jusqu'à 175 000 cas récidivants chaque année aux États-Unis et des taux de récidive élevés après un traitement antibiotique. Des études précliniques ont montré la supériorité de REC-3964 par rapport au bezlotoxumab, et les essais de phase 1 ont démontré sa sécurité et sa tolérabilité. L'essai de phase 2 ALDER recrutera environ 80 participants aux États-Unis et en Europe pour évaluer la sécurité, la tolérabilité, la pharmacocinétique et l'efficacité.

Recursion (NASDAQ: RXRX) hat den ersten Patienten in seiner Phase-2-Studie für REC-3964 behandelt, einem oralen, nicht-antibiotischen kleinen Molekül, das für wiederkehrende Clostridioides difficile (C. diff) Infektionen entwickelt wurde. Die neuartige Behandlung hemmt selektiv die Glucosyltransferase-Aktivität des von C. diff produzierten Toxins B, mit dem Ziel, Rückfälle zu verhindern und gleichzeitig das Mikrobiom des Darms zu schonen. C. diff-Infektionen verursachen erhebliche Morbidität und Mortalität, mit bis zu 175.000 wiederkehrenden Fällen jährlich in den USA und hohen Rückfallraten nach einer antibiotischen Behandlung. Vorklinische Studien zeigten die Überlegenheit von REC-3964 im Vergleich zu Bezlotoxumab, und Phase-1-Studien demonstrierten die Sicherheit und Verträglichkeit. Die Phase-2-Studie ALDER wird rund 80 Teilnehmer in den USA und Europa einschreiben, um Sicherheit, Verträglichkeit, Pharmakokinetik und Wirksamkeit zu bewerten.

Positive
  • REC-3964 is a first-in-class, non-antibiotic treatment for C. diff, potentially reducing recurrence rates.
  • Preclinical studies showed REC-3964's superiority over bezlotoxumab.
  • Phase 1 studies demonstrated REC-3964's safety and tolerability.
  • The Phase 2 trial aims to address a significant unmet medical need, potentially reducing healthcare costs.
Negative
  • High recurrence rates of C. diff infection post-antibiotic treatment pose ongoing challenges.

Insights

The initiation of Phase 2 clinical trials for REC-3964 marks a significant milestone in addressing the critical issue of recurrent Clostridioides difficile (C. diff) infections. This potential first-in-class oral treatment offers a novel approach by targeting the bacterial toxin without disrupting the gut microbiome, a common drawback of antibiotic treatments.

Key points to consider:

  • REC-3964's unique mechanism of action could provide a much-needed alternative to antibiotics, potentially reducing recurrence rates and associated healthcare costs.
  • The drug's development through Recursion's Operating System showcases the company's innovative TechBio approach, potentially validating their platform for future drug discoveries.
  • Positive preclinical and Phase 1 results suggest a promising safety profile, which is important for addressing the 175,000 annual cases of recurrent C. diff in the US alone.

If successful, REC-3964 could significantly impact the $2 billion annual healthcare cost associated with recurrent C. diff infections, offering both clinical and economic benefits.

Recursion's advancement of REC-3964 to Phase 2 trials is a positive development for the company, potentially strengthening its position in the biotech sector. Key financial implications include:

  • Market opportunity: Targeting a segment with $2 billion annual healthcare costs indicates significant revenue potential if the drug succeeds.
  • Platform validation: As the first new chemical entity from RecursionOS to reach Phase 2, success could validate the company's AI-driven approach, potentially attracting partnerships or investments.
  • R&D efficiency: The AI-driven drug discovery process may lead to reduced development costs and faster time-to-market, improving Recursion's financial outlook.
  • Competitive advantage: A novel, non-antibiotic approach could capture market share from existing treatments, especially if it demonstrates superior efficacy in preventing recurrence.

While it's too early to quantify the financial impact, positive Phase 2 results could be a significant catalyst for Recursion's stock price, given its current market cap of $1.96 billion.

  • REC-3964 is Recursion’s first new chemical entity developed using the RecursionOS.
  • REC-3964 represents a novel, non-antibiotic approach with a unique mechanism of action that binds and blocks catalytic activity of the toxin's innate glucosyltransferase in order to inhibit the toxin produced by C. diff. in the gastrointestinal tract.
  • There are up to 175,000 cases of recurrent C. diff. each year and more than 29,000 patients die in the U.S. from C. diff. annually. Rates of recurrent C. diff. have increased significantly in recent years, representing a major public health challenge.

SALT LAKE CITY, Oct. 22, 2024 (GLOBE NEWSWIRE) -- Recursion (NASDAQ: RXRX), a leading clinical stage TechBio company decoding biology to radically improve lives, today announced that the first patient has been dosed in its Phase 2 clinical trial of REC-3964, a potential first-in-class, oral small molecule and new chemical entity for the treatment of recurrent Clostridioides difficile infection. C. diff is a toxin producing bacteria that causes diarrhea and colitis, and can be life threatening. Up to 730,000 cases are estimated to occur in the U.S. and EU5 annually, and the infection is responsible for an estimated 29,000 deaths in the U.S. each year. Recursion’s study will initially address the recurrent C. diff. (up to 175,000 cases in the United States per year) population, which costs the healthcare system approximately two billion dollars per year.

Increasing cases of recurrent C. diff. infections pose significant public health challenges. Antibiotics, the standard treatment for C. diff. infections, disturb the gut microbiome due to their non-selective nature. Despite initial success, antibiotics fail to prevent recurrence in 20-30% of primary cases. Further, the risk of subsequent recurrence rises to 40% after the first and 45-65% after two or more.

REC-3964 is the first novel small molecule developed through Recursion’s Operating System, and selectively inhibits the glucosyltransferase activity of toxin B produced by C. diff in the gastrointestinal tract, offering a unique mechanism of action. Unlike antibiotics, which disrupt the gut microbiome, REC-3964 precisely targets the bacterial toxin while sparing healthy tissue, potentially minimizing adverse events. It is being studied as part of a treatment regimen to prevent recurrent C. diff infections, a leading cause of antibiotic-associated diarrhea that can lead to significant morbidity and mortality.

Presented at the 6th Edition of World Congress on Infectious Diseases, preclinical studies demonstrated its superiority over bezlotoxumab in a human disease-relevant C. diff. hamster model. Additionally, Phase 1 studies in healthy volunteers showed REC-3964 was well tolerated with no serious adverse events (SAEs), underscoring its potential safety and tolerability.

“There’s a significant unmet need for new treatment options for patients with C. diff. infection that are easier to use and more cost effective,” said Chris Gibson, Ph.D., Co-Founder and CEO of Recursion. “We are encouraged by the progress of REC-3964, the first new chemical entity from our platform to advance to Phase 2 clinical trials, and now, to the first patient dosed. We look forward to continuing to advance this trial to help patients in need and drive down billions in costs to the healthcare system for treatment.”

Christian John Lillie, Co-Founder and CEO of the Peggy Lillis Foundation, shared: "We are so pleased to learn that our partner Recursion has initiated its ALDER trial. All new therapies that can be added to the known standard of care have the potential to decrease the physical and emotional suffering of recurrent C. diff. on patients and the significant burden to the health care system.”

“Patients with C. diff face significant challenges, with 20-30% of initial infections recurring after standard treatment and a 40% chance of further recurrence, often leading to severe complications and a diminished quality of life,” said Najat Khan, Ph.D., Chief Commercial Officer and Chief R&D Officer at Recursion. “For these patients and their families, the need for safe, effective, non-antibiotic treatment options is critical. REC-3964 offers a novel, targeted approach by selectively inhibiting the bacterial toxin while sparing the host. With encouraging preclinical data and strong tolerability demonstrated in Phase 1 studies, it’s particularly rewarding to see the first drug developed using the RecursionOS and advancing to Phase 2 trials.”

The Phase 2 ALDER clinical trial is a multi-center randomized study to investigate the safety, tolerability, pharmacokinetics (PK) and efficacy of REC-3964 at doses of either 250 mg or 500 mg for the reduction of C. diff. and will include an observation only arm. Approximately 80 individuals will ultimately be enrolled in the study across the U.S. and Europe.

About Clostridioides difficile infection
Clostridioides difficile (C. diff.) infection is a bacterial disease that impacts more than 730,000 people in the U.S. and EU5 every year. Rates of recurrent C. diff. have increased significantly in recent years, representing a major public health challenge, with people 7 to 10 times more likely to get C. diff. infection while taking an antibiotic and the subsequent month. About 20-30% patients who have C. diff. infection will have it again in the subsequent 2 to 8 weeks. After the first recurrence, there’s a 40% likelihood of a second recurrence, and a 45-65% likelihood of recurrence among patients who have recurred more than twice. In total C. diff. infection is estimated to cause 29,300 deaths in the U.S. each year. More than 80% of C. diff. infection deaths occur in people aged 65 and older. On average, one in 11 patients older than 65 years diagnosed with healthcare-associated C. diff. infection will die within a month. Extended stays in healthcare settings, such as hospitals and nursing homes, also increase risk.

About REC-3964
REC-3964 is a potential first-in-class, orally bioavailable non-antibiotic small molecule that is being investigated for the potential treatment of recurrent Clostridioides difficile (C. diff.) infection. This selective inhibitor is Recursion’s first new chemical entity to reach the clinic, and binds and blocks catalytic activity of the toxin's innate glucosyltransferase. In preclinical studies, REC-3964 was found to be superior to bezlotoxumab in a human disease relevant C. diff. hamster model, with significant difference in probability of survival versus bezlotoxumab alone at the end of treatment. REC-3964 was also well tolerated in Phase 1 healthy volunteer studies, demonstrating potential safety and tolerability with no serious adverse events (SAEs).

About the Trial
Our Phase 2 ALDER clinical trial is a multi-center, open-label study to investigate the safety, tolerability, pharmacokinetics (PK) and efficacy of REC-3964 (doses of either 250 mg or 500 mg PO every 12 hours) for the reduction of Clostridioides Difficile infection (C. diff.). Approximately 80 individuals will be enrolled in this open-label Phase 2 study, randomized 1:2:1 to receive oral doses of REC-3964, 250 mg, 500 mg or observation. The purpose of this study is to investigate the safety, tolerability, pharmacokinetics (PK) and efficacy of REC-3964 for the reduction of recurrent Clostridioides difficile infection (rCDI) after initial cure with vancomycin. Participants will receive treatment with REC-3964 for 28 days.

About Recursion
Recursion (NASDAQ: RXRX) is a clinical stage TechBio company leading the space by decoding biology to radically improve lives. Enabling its mission is the Recursion OS, a platform built across diverse technologies that continuously generate one of the world’s largest proprietary biological and chemical datasets. Recursion leverages sophisticated machine-learning algorithms to distill from its dataset a collection of trillions of searchable relationships across biology and chemistry unconstrained by human bias. By commanding massive experimental scale — up to millions of wet lab experiments weekly — and massive computational scale — owning and operating one of the most powerful supercomputers in the world, Recursion is uniting technology, biology and chemistry to advance the future of medicine.

Recursion is headquartered in Salt Lake City, where it is a founding member of BioHive, the Utah life sciences industry collective. Recursion also has offices in Toronto, Montréal, London, and the San Francisco Bay Area. Learn more at www.Recursion.com, or connect on X (formerly Twitter) and LinkedIn.

Media Contact
Media@Recursion.com

Investor Contact
Investor@Recursion.com

Forward-Looking Statements

This document contains information that includes or is based upon “forward-looking statements” within the meaning of the Securities Litigation Reform Act of 1995, including, without limitation, those regarding the potential efficacy of REC-3964; timing of the Phase 2 clinical trial of REC-3964; early and late stage discovery, preclinical, and clinical programs; licenses and collaborations; prospective products and their potential future indications and market opportunities; Recursion OS and other technologies; business and financial plans and performance; and all other statements that are not historical facts. Forward-looking statements may or may not include identifying words such as “plan,” “will,” “expect,” “anticipate,” “intend,” “believe,” “potential,” “continue,” and similar terms. These statements are subject to known or unknown risks and uncertainties that could cause actual results to differ materially from those expressed or implied in such statements, including but not limited to: challenges inherent in pharmaceutical research and development, including the timing and results of preclinical and clinical programs, where the risk of failure is high and failure can occur at any stage prior to or after regulatory approval due to lack of sufficient efficacy, safety considerations, or other factors; our ability to leverage and enhance our drug discovery platform; our ability to obtain financing for development activities and other corporate purposes; the success of our collaboration activities; our ability to obtain regulatory approval of, and ultimately commercialize, drug candidates; our ability to obtain, maintain, and enforce intellectual property protections; cyberattacks or other disruptions to our technology systems; our ability to attract, motivate, and retain key employees and manage our growth; inflation and other macroeconomic issues; and other risks and uncertainties such as those described under the heading “Risk Factors” in our filings with the U.S. Securities and Exchange Commission, including our Annual Report on Form 10-K and Quarterly Reports on Form 10-Q. All forward-looking statements are based on management’s current estimates, projections, and assumptions, and Recursion undertakes no obligation to correct or update any such statements, whether as a result of new information, future developments, or otherwise, except to the extent required by applicable law.


FAQ

What is REC-3964?

REC-3964 is an oral, non-antibiotic small molecule developed by Recursion for treating recurrent Clostridioides difficile infections by selectively inhibiting the bacterial toxin.

What is the purpose of Recursion's Phase 2 clinical trial for REC-3964?

The Phase 2 clinical trial aims to investigate the safety, tolerability, pharmacokinetics, and efficacy of REC-3964 in reducing recurrent C. diff infections.

What were the results of the Phase 1 trial for REC-3964?

The Phase 1 trial demonstrated that REC-3964 was well tolerated with no serious adverse events.

How many participants will be enrolled in the Phase 2 ALDER trial for REC-3964?

Approximately 80 participants will be enrolled across the U.S. and Europe.

What is the significance of REC-3964's mechanism of action?

REC-3964 offers a unique mechanism by selectively inhibiting the glucosyltransferase activity of toxin B produced by C. diff, potentially reducing recurrence without disrupting the gut microbiome.

Recursion Pharmaceuticals, Inc.

NASDAQ:RXRX

RXRX Rankings

RXRX Latest News

RXRX Stock Data

2.23B
267.06M
4.52%
94.07%
21.78%
Biotechnology
Biological Products, (no Disgnostic Substances)
Link
United States of America
SALT LAKE CITY